Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    21945698 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9
Conditions: Acellular Pertussis;   Tetanus;   Diphtheria
Interventions: Procedure: Taking of blood samples;   Biological: Boostrix;   Biological: Adacel

Study has passed its completion date and status has not been verified in more than two years.